Cantor Fitzgerald Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)
In a report released yesterday, Steven Seedhouse from Cantor Fitzgerald maintained a Buy rating on Apellis Pharmaceuticals, with a price target of $31.00. The company’s shares closed yesterday at $18.82.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Seedhouse covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Korro Bio, and CAMP4 Therapeutics Corporation. According to TipRanks, Seedhouse has an average return of 9.9% and a 43.11% success rate on recommended stocks.
In addition to Cantor Fitzgerald, Apellis Pharmaceuticals also received a Buy from Roth MKM’s Adam Walsh in a report issued on March 13. However, on March 5, Mizuho Securities maintained a Hold rating on Apellis Pharmaceuticals (NASDAQ: APLS).
Based on Apellis Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $199.91 million and a GAAP net loss of $58.95 million. In comparison, last year the company earned a revenue of $212.53 million and had a GAAP net loss of $36.35 million
Based on the recent corporate insider activity of 77 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of APLS in relation to earlier this year. Last month, Mark Jeffrey DeLong, the Chief Business & Strat Officer of APLS sold 368.00 shares for a total of $8,151.20.
Read More on APLS:
